Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Inovio Pharmaceuticals Reports 2015 Second Quarter Results; Conference Call Will Discuss New Cancer Partnership
August 10, 2015 11:34 AM EDT
Stifel analyst Thomas Shrader reiterated a Buy rating and $19 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced Q2 results and a broad partnership with MedImmune to develop INO-3112 in combination with MedImmunes collection of IO molecules.
Shrader said he likes the deal.... More
August 10, 2015 11:19 AM EDT
Piper Jaffray analyst Charles Duncan reiterated his Overweight rating and $31 price target on Inovio Pharmaceuticals (NASDAQ: INO) after the company announced 2Q financials and a partnership with AstraZeneca worth up to $700M ($27.5M upfront + potential development, regulatory, and commercialization milestones) plus tiered double... More
August 10, 2015 6:53 AM EDT
Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $5.52 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
...
More
